Clinical Genomics and Experimental Therapeutics

临床基因组学和实验治疗学

• 批准号: 9362209
• 负责人: Falk Lohoff
• 金额: $ 276.35万
• 依托单位: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9362209
• 关键词: Affect; Affective; Anxiety Disorders; Area; Biological Markers; Clinical; Clinical Research; DNA Sequence; Dopamine; Emotions; Epigenetic Process; Fright; Functional Imaging; Functional disorder; Genetic; Genomics; Genotype; Human; Individual Differences; Intervention; Investigational Therapies; Methods; Molecular; Neurobiology; Neurons; Other Genetics; Pharmacogenetics; Pharmacological Treatment; Phase; Post-Traumatic Stress Disorders; Process; Proteomics; Regulation; Research; Risk; Signal Transduction; Subgroup; Translating; Treatment outcome; Work; addiction; alcohol use disorder; base; dopamine transporter; emotion regulation; genetic approach; genome-wide; human population genetics; imaging genetics; interest; molecular marker; neurobiological mechanism; next generation; novel therapeutics; pre-clinical; precision medicine; preclinical study; problem drinker; research study; transcriptome sequencing; treatment response

Section on Clinical Genomics and Experimental Therapeutics (SCGET) 1. Conducts pre-clinical studies and translational clinical studies with focus on genomics and epigenetics related to the pathophysiology and treatment of alcohol use disorders and addictions. 2. Pre-clinical work focuses on identifying molecular mechanisms involved in addictions, utilizing a wide array of methods including human population genetics, genome wide genotyping approaches, next-generation DNA and RNA sequencing, and epigenetic/proteomic profiling. 3. Findings are translated into human clinical studies using molecular biomarker, pharmacogenetic, epigenetic and functional imaging genetic approaches. 4. Clinical studies include early phase 1 / phase 2 proof-of-concept studies of experimental novel therapeutics guided by molecular biomarker profiling.

临床基因组学和实验治疗学（SCGET） 1.开展临床前研究和转化临床研究，重点关注基因组学 与酒精使用障碍的病理生理学和治疗有关的表观遗传学， 上瘾 2.临床前工作的重点是确定参与成瘾的分子机制， 利用广泛的方法，包括人类群体遗传学，全基因组， 基因分型方法，下一代DNA和RNA测序，以及 表观遗传/蛋白质组学分析。 3.这些发现被转化为使用分子生物标志物的人类临床研究， 药物遗传学、表观遗传学和功能成像遗传学方法。 4.临床研究包括早期的1期/2期概念验证研究， 通过分子生物标志物分析指导的新疗法。